StockMacro
Company, fund or insider

Help

Menu

Priya Singhal

Insider (Form 4 reporting owner): Head of Development CIK 1769608Name as filed: Singhal PriyaIts filings on EDGARAll insiders

Measures activity, not value. Not investment advice.

Since 28 Mar 2023, sold $2.0M in 16 sales (15 under a 10b5-1 plan set in advance) of Biogen.

Companies

Role on the latest Form 4 for each; open-market trades counted
CompanyRoleTrades fromtoPurchasesSales
Biogen BIIBHead of Development28 Mar 20239 Feb 2026–16$2.0M

What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.

Median return minus the sector fund, in percentage points; "too few trades" under 5
Open-market tradesAfter 3 monthsAfter 6 monthsAfter 12 months
After sales-3.1 pts12 trades, 42% above the sector-12.1 pts12 trades, 25% above the sector-34.9 pts11 trades, 27% above the sector

For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.

By year

Counted open-market trades, by trade date
YearPurchasesBoughtSalesSoldNet
2026––2$666K-$666K
2025––2$550K-$550K
2024––7$463K-$463K
2023––5$345K-$345K

Every trade

16, newest first; open-market purchases and sales only
Trade dateCompanySideSharesPriceValuePlanned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. Filing
9 Feb 2026Biogen BIIBSellafter exercising options2,660$199.83$532K10b5-1 planForm 4filed 10 Feb 2026
2 Feb 2026Biogen BIIBSellafter exercising options748$179.30$134K10b5-1 planForm 4filed 3 Feb 2026
2 Sep 2025Biogen BIIBSellafter exercising options517$133.55$69K10b5-1 planForm 4filed 2 Sep 2025
19 May 2025Biogen BIIBSell3,806$126.25$481K10b5-1 planForm 4filed 20 May 2025
9 Dec 2024Biogen BIIBSellafter exercising options110$157.21$17K10b5-1 planForm 4filed 9 Dec 2024
3 Sep 2024Biogen BIIBSellafter exercising options431$204.22$88K10b5-1 planForm 4filed 5 Sep 2024
2 Apr 2024Biogen BIIBSell93$213.09$20K10b5-1 planForm 4filed 3 Apr 2024
22 Feb 2024Biogen BIIBSell262$221.23$58K10b5-1 planForm 4filed 26 Feb 2024
16 Feb 2024Biogen BIIBSellafter exercising options108$221.49$24K10b5-1 planForm 4filed 21 Feb 2024
12 Feb 2024Biogen BIIBSellafter exercising options419$239.45$100K10b5-1 planForm 4filed 13 Feb 2024
2 Feb 2024Biogen BIIBSellafter exercising options634$245.93$156K10b5-1 planForm 4filed 5 Feb 2024
11 Dec 2023Biogen BIIBSellafter exercising options110$248.00$27K10b5-1 planForm 4filed 12 Dec 2023
5 Sep 2023Biogen BIIBSellafter exercising options431$269.43$116K10b5-1 planForm 4filed 6 Sep 2023
3 Jul 2023Biogen BIIBSellafter exercising options81$282.87$23K10b5-1 planForm 4filed 5 Jul 2023
4 Apr 2023Biogen BIIBSell91$277.11$25K10b5-1 planForm 4filed 6 Apr 2023
28 Mar 2023Biogen BIIBSell568$270.06$153KNoForm 4filed 30 Mar 2023

From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.